Literature DB >> 4008939

The influence of methods of production, purification and storage of monoclonal antibodies upon their observed specificities.

P A Underwood, P A Bean.   

Abstract

A panel of 38 monoclonal antibodies was exposed to a variety of physical conditions commonly used in their purification and storage. Reactivity with the homologous (immunising) antigen was reduced in a significant proportion (42%) of antibodies following these physical treatments. Sensitivity to particular physical treatments correlated with antibody subclass. In 3 cases the relative specificity of the antibody (as measured by cross-reactivity with 16 closely related antigens) was also altered. Following passage of the cloned hybridomas as ascites, 3 antibodies exhibited marked differences in specificity, which suggested the selection of different genotypes. The importance of documenting the methods of production, purification and storage of particular monoclonal antibodies used in comparative assay is stressed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4008939     DOI: 10.1016/0022-1759(85)90020-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Analytical approaches to the study of monoclonal antibody stability.

Authors:  W Jiskoot; E C Beuvery; A A de Koning; J N Herron; D J Crommelin
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

2.  Immobilization of proteins (antibodies) to supports with a constantly high retention of immunoreactivity involving the formation of a Schiff-base and subsequent reduction to a secondary amine with sodium borohydride or sodium cyanoborohydride has been problematical.

Authors:  P Grandics
Journal:  Appl Biochem Biotechnol       Date:  1987-08       Impact factor: 2.926

3.  The influence of sucrose, dextran, and hydroxypropyl-beta-cyclodextrin as lyoprotectants for a freeze-dried mouse IgG2a monoclonal antibody (MN12).

Authors:  M E Ressing; W Jiskoot; H Talsma; C W van Ingen; E C Beuvery; D J Crommelin
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.